The World Congress on Controversies in Neurology

Welcome Note
Scientific Program
Poster Presentations
General Information
Accompanying Persons’ Program
Past & Future CONy Congresses

The World Congress on Controversies in Neurology
The World Congress on Controversies in Neurology
 Sponsors   Registration   Accommodation   Contact 

Scientific Program

Thursday, September 6, 2007

16:00-18:00 Plenary Session


Opening remarks

  A.D. Korczyn, Israel

V. Hachinski, Canada

K. Einhaeupl, Germany



The role of controversies in the growth of knowledge


M. Dascal, Israel


Cognitive agnosia: An underdiagnosed cause of controversies


V. Hachinski, Canada


Accelerating drug discovery by venture philanthropy


H. Fillit, USA



Welcome Reception

Friday, September 7, 2007
Hall A

Session 1    


Multiple Sclerosis (MS)
Sponsored by an unrestricted grant from Biogen Idec


Capsule: Many people believe that MS is a syndrome rather than a single nosologic entity. The role of auto-immune processes is also still problematic and the respective role of T cells and B cells is debated. This has important implications for therapy.

Chairpersons: G. Comi, Italy; Z. Stelmasiak, Poland


Debate: MS is a single nosologic entity due to an auto-immune mechanism


Yes: H.P. Hartung, Germany


No: I. Steiner, Israel



Alemtuzumab (Campath) in early MS


V. Brinar, Croatia



Coffee Break

Session 2  


Anti-Interferon Antibodies
Sponsored by an unrestricted grant from TEVA & Sanofi Aventis

Capsule: Treatment with interferons (IFNs) provokes in some cases the production of naturalizing antibodies (NABs). Their clinical significance is still unclear and their management is still under debate.

  Chairpersons: V. Brinar, Croatia; A. Miller, Israel


Weak points in MS diagnosis


G. Giovannoni, UK


Role of Biomarkers in diagnosis and treatment


K. Selmaj, Poland




Debate: Does the presence of NABs against IFNs necessitate a switch to another class of therapy


Yes: P.S. Sorensen, Denmark 

 No: J. Oger, Canada



Lunch Break



Session 3  


Treatment Strategies for Multiple Sclerosis
Sponsored in part by an unrestricted grant from Bayer Schering Pharma


Capsule: Many issues regarding when and how to start treatment and what are the future avenues are not clear!

  Chairpersons: W. Carroll, Australia; K. Rejdak, Poland


Debate: Clinically isolated syndromes (CIS): to treat or not to treat


Start early: G. Comi, Italy


No hurry: A. Siva, Turkey




Debate: Is stem cell therapy an imminent treatment in advanced MS?


Stem cell therapy in MS is a real option: G. Martino, Italy


Bioethical aspects of human embryonic stem cells are still an issue: M. Revel, Israel

15:30-16:00 Coffee  Break
Session 4  
Multiple sclerosis - Neuroproctection
  Sponsored in part by an unrestricted grant from Merck Serono
  Capsule: While there is no doubt that interferons and copaxone can reduce relapse rate in MS, it is still unclear if, how, and to what extent they can reduce the Accumulation of disability.
  Chairpersons: G. Comi, Italy; I. Milonas, Greece
 16:00-17:00 Debate: Neuroprotective effect of IFNs and copaxone in MS - myth or reality?
  Myth: C. Constantinescu, UK
  Reality: X. Montalban, Spain
Session 5  
17:00-18:00 Free Communications -Multiple sclerosis
  Chairpersons: P. Calabrese, Germany; M. Sakkopoulou, Greece
Immediate treatment with IFNB-1b after a first event suggestive of MS delays persistant neurological impairment
  X. Montalban, Spain
Use of stem cells preparations for the treatment of patients suffering from multiple sclerosis adn immunological control of treatment efficiency
  N. Mkrtchyan, Russia
Comparison of interferon beta productions and azathioprine in treatment of relapsing-remitting multiple sclerosis
  M. Janghorbani, Iran
17:45-18:00 Facial Palsy in Iranian patients with Multiple Sclerosis
  Y. IIkhchoui, Iran

Friday, September 7, 2007
Hall B
Session 6  


Management of Transient Ischemic Attacks (TIA’s)


Capsule: TIA’s are frequently undiagnosed, misdiagnosed or mistreated.


Chairpersons: N. Bornstein, Israel; K. Einhaeupl, Germany



Debate: Testing for right-to-left cardiac shunt


The PFO should be closed before the first cerebral event: B. Meier, Switzerland

  No: The cost is too high, the yield too low: C. Diener, Germany


When and how to look for CADASIL and Fabry?

A. Rolfs, Germany



Coffee Break

Session 7  


Interventions in Secondary Stroke Prevention

  Chairpersons:  O. Bajenaru, Romania; O. Bartko, Slovakia


Debate: Drug therapy for TIA


Immediate aspirin and dipyridamole: C. Diener, Germany 


Immediate clopidogrel: J. Streifler, Israel



Debate: Carotid stenting is better than carotid endarterectomy


Capsule: Stenting is an effective procedure and in time may replace surgery for most patients.


Yes: J. Wojczal, Poland


No: N. Bornstein, Israel




Lunch Break



Session 8  


Management of Acute Stroke


Capsule: Patients with acute stroke are frequently admitted to general medical or neurological wards, where important factors are not attended to, leading to clinical deterioration

  Chairpersons: V. Hachinksi, Canada; J. Streifler, Israel
13:30-14:00 Management of hyperglycemia and hypertension in acute stroke
G.M. Boysen, Denmark
14:00-14:30 tPA beyond time and age limits
E. Stolz, Germany
14:30-15:00 Intra-arterial thrombolysis
A. Ciccone, Italy





Coffee Break



Session 9  


Pathogenesis of Parkinson's Disease (PD)
Sponsored in part by unrestricted grants from SCHWARZ PHARMA and ORION


Capsule: Despite much research, the pathogenesis of PD is still contested. Is there one cause that can be thought of as initiating the cascade?


Chairpersons: V. Kostic, Serbia; M. Ghabaee, Iran



PD is a mitochondrial dysfunction disease


M. Youdin, Israel


PD is due to protein dysfunction


W. Olanow, USA


Is PD a ferrinopathy?


D. Berg, Germany


Olfactory dysfunction in early PD suggests that the disease is caused by a toxin


H. Reichmann, Germany

Session 10  
18:00-18:30 Free Communications - Various Topics 
  Chairpersons: K. Bayulkem, Turkey; J. Wojczal, Poland 
18:00-18:10 Visual loss in idiopathic intracranial hypertension despite normal intracranial pressure
  H.E. Killer, Switzerland
18:10-18:20  Aspirin resistance correction in the aged patients after first ever ischemic stroke
  V.G. Karepov, Israel

Z. Rozhkova, Ukraine


Friday, September 7, 2007
Hall C

Session 11  
Autoimmune Dementia
Capsule: In addition to the common causes of dementia, some patients are thought to have an underlying autoimmune mechanism. When should these be considered and how should they be treated?
Chairpersons: A. Kertesz, Canada; T.A. Treves, Israel
A. Chaudhuri, UK 
A. Vincent, UK
 J. Chapman, Israel
  P. Calabrese, Germany
Session 12  
Coffee Break
A Cure for Alzheimer's Disease (AD)
Capsule: Because beta-amyloid is a hallmark of AD, attempts are being made to eliminate this protein. One of the new methods to achieve this is through anti-amyloid immunization, while a competitive method is by inhibition of APP-cleaving enzymes.
  Chairpersons: J. Callaway, USA; M. Youdim; Israel 
Debate: Immunization will cure AD
Yes: R. Nitsch, Switzerland
No: E. Giacobini, Switzerland
Session 13  
Treatment of Cognitive Impairment
Capsule: Cholinesterase inhibitors (ChEI's) and memantine are the only approved drugs for the treatment of Alzheimer’s disease (AD), but there is debate on their efficacy, both in MCI and (even more) in advanced AD.
Chairpersons: L. Battistin, Italy; D. Muresanu, Romania
M. Youdim, Israel
H. Fillit, USA
Lunch Break
Session 14  
Non-Alzheimer Dementias
Chairpersons: M. Davidson, Israel; P.J. Visser, The Netherlands 
Debate: Vascular cognitive impairment is a misleading concept
Capsule: Dementia or milder forms of cognitive decline can occure following obvious strokes or in conjunction with vascular risk factors. Recently the term vascular cognitive impairment has been suggested to encompass vascular dementia, Biswanger’s disease and multi-infarct dementia. However, this term has not been unchallenged.
Yes: A. Kertesz, Canada
No: V. Hachinski, Canada
Debate: Dementia with Lewy bodies and dementia of Parkinson’s disease are the same disorder
Yes: L. Battistin, Italy
No: G. Ransmayr, Austria
Coffee Break
Session 15  
Mild Cognitive Impairment (MCI)
Capsule: Dementia typically develops insidiously. An intermediate stage between normai aging and dementia termed mild cognitive impairment (MCI) is still not well understood nor generally accepted and there is no agreement on how it should be treated.
Chairpersons: Y. Lerman, Israel; P. Werner, Israel 
Debate: Is MCI a useful concept?
Yes: S. Gauthier, Canada
No: J.C. Morris, USA
Debate: Treatment of MCI is available and should be given
Yes: L. Spiru, Romania
No: P.J. Visser, The Netherlands
Session 16  
Free Communications - Various Topics
  Chairpersons: B. Popescu, Romania; N. Razon, Israel 
18:00-18:10 Immunotherapy of neurological paraneoplastic syndromes - disappointing or effective?
  S. Michalak, Poland 


Determinants of functional loss in patients with glioma in eloquent areas: a pre and postoperative fMRI study
  V. Gonzalez-Felipe, Germany
Activated Factor VII (Novoseven) for Acute Intracerebral Hemorrhage: Experience of 15 Cases From a Single Centre
  S. Kumar, India  

Saturday, September 8, 2007
Hall A
Session 17  


Psychogenic Neurological Disorders


Capsule: Clinicians are still facing frequent difficulties in differentiating "organic" from "functional" disorders.

  Chairpersons: T. Lempert, Germany; I. Steiner, Israel


Is psychogenic dystonia a valid diagnosis?


K. Black, USA


Is Regional Sympathetic Dystrophy (RSD) - Dystonia an organic disease? 


M. Hallet, USA

C.Elger, Germany
9:30-9:50 Vertigo as a psychogenic disorder
   M. Strupp, Germany
09:50-10:00 Discussion


Coffee Break



Session 18  


Satellite Lunch Symposium
Sponsored by Elan
Can Neurodegenerative Diseases be Slowed or Reversed?
Elan's Look into the Future



12:30-12:40 Opening remarks
  A.D. Korczyn, Israel
12:40-13:20 Natalizumab and Beyond:  Elan’s Look into the future of the science of neurodegeneration
  T. Yednock, USA
13:20-13:50 Can Alzheimer’s disease progression be Slowed or reversed?
  D. Schenk, USA
13:50-14:15 Are anti-amyloid therapies the answer?
  R. Jones, USA
14:15-14:30 Q & A; Closing remarks
  A.D. Korczyn, Israel
Session 19  


Free Communications - Stroke

Chairperson: V. Karepov, Israel

Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH


J. Braun, Germany


Carotid endarterectomy vs carotid stenting - Critical overview and leader expert's opionion


D. Bartko, Slovakia

17:00-17:15  Is mannitol useful in intracerebral hemorrhage?
   U. Misra, India


Combined Therapy of tPA and UK for actute ischemic stroke


W. Zhang , China


The incidence and determinations of Sleep Apnea Syndrome in patients with spinal cord injury and stroke


T. Van Bezeij, The Netherlands

17:45-18:00 Hemidystonia in stroke


A. Subbiah, India


Saturday, September 8, 2007
Hall B

Session 20  


Autoimmune Disorders
Sponsored in part by an unrestricted grant from Talecris


Capsule: The pathogenesis of several autoimmune diseases is still unclear. What is the role of antibodies and which treatements are available?

  Chairpersons: N. Mironov, Russia; Z. Petelin Gadze, Croatia 


The autoimmune spectrum of myasthenia


A. Vincent, UK



Debate: Treatment of chronic inflammatory demyelinating neuropathy (CIDP)

Treatment with IVIG: H.P. Hartung, Germany
Other Treatments: J. Chapman, Israel


Coffee Break

Session 21  


Capsule: Patients with epilepsy who are unresponsive to drugs should be considered for surgery and the identificatin of suitable cases usually involves expensive videotaping and seizure monitoring.
  Chairpersons: S. Benbadis, USA; D. Schmidt, Germany


Debate: Is video EEG monitoring always necessary before performing epilepsy surgery?

Yes: H. Stefan, Germany


No: M.R. Sperling, USA




Debate: Deep Brain Stimulation (DBS) is ready for clinical use in refractory epilepsy


Yes: P. Boon, Belgium


No: C. Elger, Germany




 Coffee Break



Session 22  
16:30-17:30 Resistant Epilepsy 
Capsule: About 20% of epilepsy patients do not respond adequately to drugs. What is the treatment of choice?


Chairpersons: P. Boon, Belgium; C. Elger, Germany


Debate: What to do when two drugs fail?


Try a third drug: D. Schmidt, Germany


Vagal Nerve Stimulation (in suitable patients): K. Vonck, Belgium


Ablative surgery: S. Benbadis, USA


Session 23 



Free Communications- Various Topics


Chairpersons: J.T. Apter, USA; K. Vonck, Belgium



Epilepsies with occipital epileptiform discharges-electronical characteristics


M. Mazurkiewicz-Beldzinska, Poland


What role does biofeedback therapy have in the treatment of migraine


M. Rashidi, UK


Lorazepam in treatment of convulsive status epilepticus in children: A randomized controlled trial 


P. Gupta, India

18:15-18:30 Discussion 

Saturday, September 8, 2007
Hall C
Session 24  


Parkinsons Disease (PD): Early Treatment
Sponsored in part by an unrestricted grant from Merck Serono


Capsule: Motor complications are disabling complications of PD therapy. How can they be avoided?

  Chairpersons: O. Bajenaru, Romania; A. Gordin, Finland


MAOB-inhibitors should be the first line drug in early PD


A. Ludolph, Germany


Dopamine Agonists are the treatment of choice in early PD


M. Guttman, Canada


New Treatment Advances in early PD


F. Stocchi, Italy

10:00-10:30 Coffee Break
Session 25  
Neuroprotection and Neuroplasticity
Sponsored by SSNN
Capsule: One of the important issues in stroke therapy is the protection of neurons in the penumbra region. Several Studies have failed to identify treatments which could help. Why and how to overcome these difficulties? 
  Chairpersons: A. Ludolph, Germany; L. Vecsei, Hungary
10:30-10:50 Blood-brain barrier and neuroprotection
  H.S Shanker, Sweden
10:50-11:10 Vascular Protection in Stroke
  O. Bajenaru, Romania
11:10-11:30 Neuroprotection in acute ischemic stroke - Is there still hope?
  N. Bornstein, Israel
11:30-11:50 Prophylaxis in neuroprotection. An innovative approach
  L. Csiba, Hungary
11:50-12:10 Neuroprotection and neuroplasticity - a dualistic vision of a continuous process
D. Muresanu, Romania
12:10-12:30 Discussion
Session 26  
14:30-16:00 Treatment of Advanced PD
  Capsule: How can we best control the motor complications in advanced PD?  
  Chairpersons: M. Guttman, Canada;  M. Hilz, Germany 
14:30-14:50 Intraduodenal levodopa
  D. Truong, USA
14:50-15:10 Apomorphine infusions in complicated PD
  D. Dressler, Germany
15:10-15:30 Deep Brain Stimulation (DBS)
  A. Kupsch, Germany
15:30-15:50 Spheramine-cell therapy
  E. Reissig, Germany
15:50-16:00 Discussion
16:00-16:30 Coffee Break
Session 27  
16:30-17:30 Non-Motor Aspects of PD
Capsule: Non dopaminergic symptoms may be more relevant than DA-responsive motor symptoms in PD
  Chairpersons: R. Denglar, Germany; R. Rangel Guerra, Mexico 
16:30-16:50 Is dementia inevitable in PD?
  I. Litvan, USA
16:50-17:10 Daytime somnolence in PD - How to avoid and how to treat?
   K.R. Chaudhuri, UK   
17:10-17:30 Treatment for PD psychosis: Which drug is most useful in clinical practice? 
   J.M. Rabey, Israel  
Session 28  
17:30-18:30 Parkinsonian Syndromes
  Capsule: Movement disorders with Parkinsonian features have been diagnosed using different methods, using different criteria, but the basic question remains of the nosologic entities underlying these neurodegenerative diseases.
  Chairpersons: C. Falup, Romania; J.M. Rabey, Israel 
  Debate: Are PSP and CBGD the same disease?
  For: A. Kertesz, Canada 
  Against: I. Litvan, USA

Sunday, September 9, 2007
Hall A
Session 29  


Sponsored in part by an unrestricted grant fromMerz
  Chairpersons: A. Kurdi, Jordan; T.A. Treves, Israel

Debate: Dystonia - disorder of motor programming or motor execution? 

  Capsule: Dystonia is traditionally seen as an involuntary movement, leading to treatment strategies using botulinum toxin (BTX). Viewed differently, dystonia is an “unconscious“ rather than “involuntary“ movement, caused by defective “motor routines“ in the motor program. This concept suggests that BTX, when used, should be directed into the muscles causing dystonic movement and also into their antagonists. The possible feedback can affect central mechanisms and might induce long-lasting remission.
P. Kanovsky, Czech Republic
R. Rosales, Philippines


Coffee Break



Session 30  
Restless Legs Syndrome
Sponsored in part by an unrestriced grant from Schwarz Pharma

Capsule: RLS may be the most common movement disorder, but it is still underdiagnosed and there is no consensus on its treatment.

  Chairpersons: R. Horowski, Germany; A. Kupsch, Germany 

Debate: Are PLMS and RLS the same disorder?


Yes: D. Garcia-Borreguero, Spain


No: M. Zucconi, Italy


Which treatment best avoids augmentation?

  W. Paulus, Germany

Sunday, September 9, 2007
Hall B
Session 31  


Treatment of Migraine: Beyond Triptans


Capsule: Therapy of chronic headache is frequently unsatisfactory and newer methods for symptomatic therapy are needed. Botulinum toxin injections are such methods, which have still not received wide acceptance.
  Chairpersons: Y. Frank, USA; A. Siva, Turkey

Debate: Botulinum toxin in the treatment of headache


Proposition: Botulinum toxin is effective for headache
S. Evers, Germany
Opposition: Botulinum toxin should be used cautiously
U. Reuter, Germany




Coffee Break



Session 32  
Free Communications - Multiple Sclerosis
  Chairpersons: N. Mkrtchyan, Russia; J.A. Moreira, USA 
Structural and functional correction of spine and spinal cord disorders for patients affected by multiple sclerosis
  A. Sukhanov, Russia
10:40-10:50 Acquired attitude, interpersonal frictions and development of multiple sclerosis
  P. Vassiliu, Greece
Treatment outcome in multiple sclerosis patients after high-dose chemotherapy (HDCT)+autologous stem cell transplantation (ASCT): Follow up results of prospective multicenter study
  A.A. Novik, Russia
Influence of interferon-beta switching on neutralizing antibody titers: The Austrian Switch Study (ASS)
  F. Deisenhammer, Austria
Session 33  
11:10-12:00 Free Communications - Various Topics
  Chairpersons: P. Kanovsky, Czech Republic; S. Schreiber, Israel
11:10-11:20  A dramatic effect of nandrolone decanoate in cerebral palsy
  A. Al Mosawi, Iraq
Long-term use of  levetiracetam to treat tics in children and adolescents with Tourette  syndrome
  Y. Awaad, USA
Can patterns of clinical presentation in acute spinal pathology predict diagnosis and treatment in a spine surgical unit?
  T. Thangarajah, UK
11:40-11:50 Neuroleptic Malignant Syndrome
  J. Mohtashami, Iran
11:50-12:00 Implementing Transcranial Doppler as confirmatory test in brain death criteria
  B. Sheikh, Saudi Arabia
Session 34  
Optimization of Treatment Benefits in Patients with MS: Exploring the Betaferon Dose-Response Curve
Satellite Symposium Sponsored by Bayer Schering Pharma
  Chairperson: B. Carroll, Australia 
12:00-12:15 Introduction: Current management of MS
  B. Carroll, Australia 
12:15-12:45 Experience with higher doses of interferon in MS
  O. Fernandez, Spain 
12:45-13:05 Optimizing management strategies to maximize tolerability and adherence for Betaferon
  K. Baum, Germany 
13:05-13:25 The BEYOND study
  D. Goodin, USA
13:25-13:45 The potential impact of BEYOND on case management strategies
  D. Jeffery, USA
13:45-14:00 Questions and Discussion
  B. Carroll, Australia 


© All Rights Reserved 2006.